United States News All stories

Viking Therapeutics (NASDAQ:VKTX) announced the start of its SUNRISE Phase 3 clinical program for oral VK2735, an investigational therapy being developed for obesity management.

Alpha Compute (NASDAQ:ALP) announced that it entered into a binding GPU compute services agreement on October 9, 2026, for its first contracted U.S. GPU cluster.

Parabilis Medicines (NASDAQ:PBLS) announced the initiation of a new dose-ranging cohort for zolucatetide in adults with familial adenomatous polyposis, a hereditary condition associated with the development of precancerous polyps.

Takeda Pharmaceutical (NYSE:TAK) presented new data from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating TAK-881 Immune Globulin Subcutaneous (Human), 20% Solution combined with recombinant human hyaluronidase.

Entrada Therapeutics (NASDAQ:TRDA) announced that an independent monitoring committee has recommended initiating Cohort 3 of its Phase 1/2 ELEVATE-44-201 clinical study.

Fusion Fuel (NASDAQ:HTOO) reported first-half 2026 financial results and provided its outlook for the remainder of the year.

Morgan Stanley (NYSE:MS) reported third-quarter 2026 financial results, beating analyst expectations on both revenue and earnings.

State Street Corporation (NYSE:STT) reported third-quarter 2026 financial results, with adjusted earnings per share of $3.69, beating analyst expectations of $3.67.

Entrada Therapeutics (NASDAQ:TRDA) announced initial results from the first cohort of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne muscular dystrophy.

Eton Pharmaceuticals (NASDAQ:ETON) announced exclusive U.S. licensing and supply agreements with Aquestive Therapeutics (NASDAQ:AQST) for LIBERVANT, a seizure-cluster treatment.

Sono-Tek (NASDAQ:SOTK) reported fiscal first-half 2027 financial results, with revenue increasing 6% year over year to $10.893 million.

Fastenal (NASDAQ:FAST) reported third-quarter 2026 financial results, delivering higher-than-expected revenue and earnings.

Bank of America (NYSE:BAC) reported third-quarter 2026 financial results with adjusted earnings per share of $1.08, compared with analyst expectations of $1.10.

National Fuel Gas (NYSE:NFG) announced that its board of directors approved a plan to spin off its Integrated Upstream and Gathering (IUG) business into a separate public company.

Quoin Pharmaceuticals (NASDAQ:QNRX) announced that the European Medicines Agency has granted orphan drug designation to QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disorder.

Ocugen (NASDAQ:OCGN) entered an agreement granting Roots Pharmaceutical exclusive regional rights to OCU400, an investigational gene therapy for retinitis pigmentosa, an inherited vision-loss disease.

BlackRock (NYSE:BLK) reported third-quarter 2026 financial results with revenue of $7.8 billion, representing a 19% increase compared with the same period last year.

Verastem Oncology (NASDAQ:VSTM) reported updated Phase 1/2 TARGET-D 101 trial results for VS-7375, an investigational oral KRAS G12D inhibitor, across multiple KRAS G12D-mutated solid tumors.

Yiren Digital (NYSE:YRD) reaffirmed its intention to continue implementing its previously announced share repurchase program of up to US$20 million.

High Templar Tech (NYSE:HTT) reported first-half 2026 shareholder net income of RMB416.9 million, compared with RMB461.9 million in the same period last year.

Oil prices moved higher after vessels were struck in the Strait of Hormuz and Iranian officials said new tactics were being used to target ships in the region.

Rhythm Pharmaceuticals (NASDAQ:RYTM) commercially launched IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity following its inclusion on the national insurance price list.

Alvotech (NASDAQ:ALVO) and Advanz Pharma submitted a regulatory application in Europe for AVT29, a proposed biosimilar referencing Eylea 8 mg, a treatment used for retinal diseases.

ASML (NASDAQ:ASML) reported third-quarter 2026 results with net sales of €11.7 billion, compared with higher profitability in the previous quarter due to improved gross margin and net income.